Pharma Mar (FRA:PMRA) Cyclically Adjusted PB Ratio: (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PMRA Pharma Mar SA FRA:PMRA
80 GF Score
Price €78.95
GF Value €82.61
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharma Mar  (FRA:PMRA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pharma Mar Cyclically Adjusted PB Ratio Related Terms


Pharma Mar Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Cyclically Adjusted PB Ratio Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.56 13.47 7.18 12.23 10.10

Pharma Mar Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.40 12.77 10.10 11.29 0.00

FRA:PMRA vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted PB Ratio falls into.


FRA:PMRA
80GF Score
Pharma Mar SA FRA:PMRA
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pharma Mar's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Pharma Mar's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.476/130.5100*130.5100
=14.476

Current CPI (Jun. 2026) = 130.5100.

Pharma Mar Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.256 99.737 4.261
201612 2.843 101.842 3.643
201703 2.713 100.896 3.509
201706 2.558 101.848 3.278
201709 2.125 101.524 2.732
201712 1.457 102.975 1.847
201803 1.385 102.122 1.770
201806 1.628 104.165 2.040
201809 1.743 103.818 2.191
201812 1.159 104.193 1.452
201903 0.618 103.488 0.779
201906 0.007 104.612 0.009
201909 -0.287 103.905 -0.360
201912 0.615 105.015 0.764
202003 4.398 103.469 5.547
202006 5.847 104.254 7.320
202009 5.406 103.521 6.815
202012 5.671 104.456 7.085
202103 7.025 104.857 8.744
202106 7.430 107.102 9.054
202109 7.951 107.669 9.638
202112 9.878 111.298 11.583
202203 11.204 115.153 12.698
202206 11.438 118.044 12.646
202209 11.735 117.221 13.065
202212 12.313 117.650 13.659
202303 12.070 118.948 13.243
202306 11.698 120.278 12.693
202309 11.589 121.343 12.465
202312 10.966 121.300 11.799
202403 11.005 122.762 11.700
202406 10.342 124.409 10.849
202409 10.485 123.121 11.114
202412 11.855 124.753 12.402
202503 11.282 125.531 11.730
202506 11.561 127.251 11.857
202509 11.500 126.840 11.833
202512 14.507 128.400 14.745
202603 14.427 129.860 14.499
202606 14.476 130.510 14.476

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Pharma Mar (FRA:PMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of €78.95 is trading 4.4% below its estimated GF Value™ of €82.61. GuruFocus considers Pharma Mar to be Fairly Valued.

Key valuation signals for FRA:PMRA:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €82.61 vs. price of €78.95 (4.4% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the FRA:PMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
80GF Score

Get the complete analysis for FRA:PMRA

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.95
Price
€82.61
GF Value